Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Innate Lymphoid Cells of the Lung.

Barlow JL, McKenzie ANJ.

Annu Rev Physiol. 2019 Feb 10;81:429-452. doi: 10.1146/annurev-physiol-020518-114630.

PMID:
30742786
2.

Roles for T/B lymphocytes and ILC2s in experimental chronic obstructive pulmonary disease.

Donovan C, Starkey MR, Kim RY, Rana BMJ, Barlow JL, Jones B, Haw TJ, Mono Nair P, Budden K, Cameron GJM, Horvat JC, Wark PA, Foster PS, McKenzie ANJ, Hansbro PM.

J Leukoc Biol. 2019 Jan;105(1):143-150. doi: 10.1002/JLB.3AB0518-178R. Epub 2018 Sep 27.

PMID:
30260499
3.

CD1a presentation of endogenous antigens by group 2 innate lymphoid cells.

Hardman CS, Chen YL, Salimi M, Jarrett R, Johnson D, Järvinen VJ, Owens RJ, Repapi E, Cousins DJ, Barlow JL, McKenzie ANJ, Ogg G.

Sci Immunol. 2017 Dec 22;2(18). pii: eaan5918. doi: 10.1126/sciimmunol.aan5918.

4.

Type-2 innate lymphoid cells in human allergic disease.

Barlow JL, McKenzie AN.

Curr Opin Allergy Clin Immunol. 2014 Oct;14(5):397-403. doi: 10.1097/ACI.0000000000000090. Review.

5.

MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion.

Oliphant CJ, Hwang YY, Walker JA, Salimi M, Wong SH, Brewer JM, Englezakis A, Barlow JL, Hams E, Scanlon ST, Ogg GS, Fallon PG, McKenzie AN.

Immunity. 2014 Aug 21;41(2):283-95. doi: 10.1016/j.immuni.2014.06.016. Epub 2014 Jul 31.

6.

The TNF-family cytokine TL1A promotes allergic immunopathology through group 2 innate lymphoid cells.

Meylan F, Hawley ET, Barron L, Barlow JL, Penumetcha P, Pelletier M, Sciumè G, Richard AC, Hayes ET, Gomez-Rodriguez J, Chen X, Paul WE, Wynn TA, McKenzie AN, Siegel RM.

Mucosal Immunol. 2014 Jul;7(4):958-68. doi: 10.1038/mi.2013.114. Epub 2013 Dec 25.

7.

IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis.

Hams E, Armstrong ME, Barlow JL, Saunders SP, Schwartz C, Cooke G, Fahy RJ, Crotty TB, Hirani N, Flynn RJ, Voehringer D, McKenzie AN, Donnelly SC, Fallon PG.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):367-72. doi: 10.1073/pnas.1315854111. Epub 2013 Dec 16.

8.

A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis.

Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, Huang LC, Johnson D, Scanlon ST, McKenzie AN, Fallon PG, Ogg GS.

J Exp Med. 2013 Dec 16;210(13):2939-50. doi: 10.1084/jem.20130351. Epub 2013 Dec 9.

9.

A Trypanosoma brucei kinesin heavy chain promotes parasite growth by triggering host arginase activity.

De Muylder G, Daulouède S, Lecordier L, Uzureau P, Morias Y, Van Den Abbeele J, Caljon G, Hérin M, Holzmuller P, Semballa S, Courtois P, Vanhamme L, Stijlemans B, De Baetselier P, Barrett MP, Barlow JL, McKenzie AN, Barron L, Wynn TA, Beschin A, Vincendeau P, Pays E.

PLoS Pathog. 2013 Oct;9(10):e1003731. doi: 10.1371/journal.ppat.1003731. Epub 2013 Oct 31.

10.

IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction.

Barlow JL, Peel S, Fox J, Panova V, Hardman CS, Camelo A, Bucks C, Wu X, Kane CM, Neill DR, Flynn RJ, Sayers I, Hall IP, McKenzie AN.

J Allergy Clin Immunol. 2013 Oct;132(4):933-41. doi: 10.1016/j.jaci.2013.05.012. Epub 2013 Jun 27.

PMID:
23810766
11.

Innate lymphoid cells--how did we miss them?

Walker JA, Barlow JL, McKenzie AN.

Nat Rev Immunol. 2013 Feb;13(2):75-87. doi: 10.1038/nri3349. Epub 2013 Jan 7. Review.

PMID:
23292121
12.

Direct control of hepatic glucose production by interleukin-13 in mice.

Stanya KJ, Jacobi D, Liu S, Bhargava P, Dai L, Gangl MR, Inouye K, Barlow JL, Ji Y, Mizgerd JP, Qi L, Shi H, McKenzie AN, Lee CH.

J Clin Invest. 2013 Jan;123(1):261-71. doi: 10.1172/JCI64941. Epub 2012 Dec 21.

13.

Epithelial cell-specific Act1 adaptor mediates interleukin-25-dependent helminth expulsion through expansion of Lin(-)c-Kit(+) innate cell population.

Kang Z, Swaidani S, Yin W, Wang C, Barlow JL, Gulen MF, Bulek K, Do JS, Aronica M, McKenzie AN, Min B, Li X.

Immunity. 2012 May 25;36(5):821-33. doi: 10.1016/j.immuni.2012.03.021. Epub 2012 May 17.

14.

Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13.

Camelo A, Barlow JL, Drynan LF, Neill DR, Ballantyne SJ, Wong SH, Pannell R, Gao W, Wrigley K, Sprenkle J, McKenzie AN.

J Gastroenterol. 2012 Nov;47(11):1198-211. doi: 10.1007/s00535-012-0591-2. Epub 2012 Apr 27.

15.

Transcription factor RORα is critical for nuocyte development.

Wong SH, Walker JA, Jolin HE, Drynan LF, Hams E, Camelo A, Barlow JL, Neill DR, Panova V, Koch U, Radtke F, Hardman CS, Hwang YY, Fallon PG, McKenzie AN.

Nat Immunol. 2012 Jan 22;13(3):229-36. doi: 10.1038/ni.2208.

16.

Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity.

Barlow JL, Bellosi A, Hardman CS, Drynan LF, Wong SH, Cruickshank JP, McKenzie AN.

J Allergy Clin Immunol. 2012 Jan;129(1):191-8.e1-4. doi: 10.1016/j.jaci.2011.09.041. Epub 2011 Nov 12.

PMID:
22079492
17.

Insights into the initiation of type 2 immune responses.

Oliphant CJ, Barlow JL, McKenzie AN.

Immunology. 2011 Dec;134(4):378-85. doi: 10.1111/j.1365-2567.2011.03499.x. Review.

18.

Reciprocal expression of IL-25 and IL-17A is important for allergic airways hyperreactivity.

Barlow JL, Flynn RJ, Ballantyne SJ, McKenzie AN.

Clin Exp Allergy. 2011 Oct;41(10):1447-55. doi: 10.1111/j.1365-2222.2011.03806.x. Epub 2011 Jul 4.

PMID:
21722219
19.

Nuocytes: expanding the innate cell repertoire in type-2 immunity.

Barlow JL, McKenzie AN.

J Leukoc Biol. 2011 Nov;90(5):867-74. doi: 10.1189/jlb.0311160. Epub 2011 Jun 28. Review.

PMID:
21712394
20.

Tim1 and Tim3 are not essential for experimental allergic asthma.

Barlow JL, Wong SH, Ballantyne SJ, Jolin HE, McKenzie AN.

Clin Exp Allergy. 2011 Jul;41(7):1012-21. doi: 10.1111/j.1365-2222.2011.03728.x. Epub 2011 Apr 7.

21.

New insights into 5q- syndrome as a ribosomopathy.

Barlow JL, Drynan LF, Trim NL, Erber WN, Warren AJ, McKenzie AN.

Cell Cycle. 2010 Nov 1;9(21):4286-93. Epub 2010 Nov 22. Review.

PMID:
20980806
22.

Tim-1 is induced on germinal centre B cells through B-cell receptor signalling but is not essential for the germinal centre response.

Wong SH, Barlow JL, Nabarro S, Fallon PG, McKenzie AN.

Immunology. 2010 Sep;131(1):77-88. doi: 10.1111/j.1365-2567.2010.03276.x. Epub 2010 May 26.

23.

Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome.

Pellagatti A, Marafioti T, Paterson JC, Barlow JL, Drynan LF, Giagounidis A, Pileri SA, Cazzola M, McKenzie AN, Wainscoat JS, Boultwood J.

Blood. 2010 Apr 1;115(13):2721-3. doi: 10.1182/blood-2009-12-259705. No abstract available.

PMID:
20360478
24.

C-type lectin SIGN-R1 has a role in experimental colitis and responsiveness to lipopolysaccharide.

Saunders SP, Barlow JL, Walsh CM, Bellsoi A, Smith P, McKenzie AN, Fallon PG.

J Immunol. 2010 Mar 1;184(5):2627-37. doi: 10.4049/jimmunol.0901970. Epub 2010 Feb 3.

25.

A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.

Barlow JL, Drynan LF, Hewett DR, Holmes LR, Lorenzo-Abalde S, Lane AL, Jolin HE, Pannell R, Middleton AJ, Wong SH, Warren AJ, Wainscoat JS, Boultwood J, McKenzie AN.

Nat Med. 2010 Jan;16(1):59-66. doi: 10.1038/nm.2063. Epub 2009 Nov 22.

26.

IL-25: a key requirement for the regulation of type-2 immunity.

Barlow JL, McKenzie AN.

Biofactors. 2009 Mar-Apr;35(2):178-82. doi: 10.1002/biof.24. Review.

PMID:
19449446
27.

The C-type lectin SIGNR1 binds Schistosoma mansoni antigens in vitro, but SIGNR1-deficient mice have normal responses during schistosome infection.

Saunders SP, Walsh CM, Barlow JL, Mangan NE, Taylor PR, McKenzie AN, Smith P, Fallon PG.

Infect Immun. 2009 Jan;77(1):399-404. doi: 10.1128/IAI.00762-08. Epub 2008 Nov 3.

28.

Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma.

Ballantyne SJ, Barlow JL, Jolin HE, Nath P, Williams AS, Chung KF, Sturton G, Wong SH, McKenzie AN.

J Allergy Clin Immunol. 2007 Dec;120(6):1324-31. Epub 2007 Sep 24.

PMID:
17889290
29.

Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion.

Fallon PG, Ballantyne SJ, Mangan NE, Barlow JL, Dasvarma A, Hewett DR, McIlgorm A, Jolin HE, McKenzie AN.

J Exp Med. 2006 Apr 17;203(4):1105-16. Epub 2006 Apr 10.

30.

Brain damage after neonatal tetanus in a rural Kenyan hospital.

Barlow JL, Mung'Ala-Odera V, Gona J, Newton CR.

Trop Med Int Health. 2001 Apr;6(4):305-8.

31.

Nonpeptide renin inhibitors with good intraduodenal bioavailability and efficacy in dog.

Boyd SA, Fung AK, Baker WR, Mantei RA, Stein HH, Cohen J, Barlow JL, Klinghofer V, Wessale JL, Verburg KM, et al.

J Med Chem. 1994 Sep 16;37(19):2991-3007.

PMID:
7932521
33.

Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides.

Rosenberg SH, Spina KP, Woods KW, Polakowski J, Martin DL, Yao Z, Stein HH, Cohen J, Barlow JL, Egan DA, et al.

J Med Chem. 1993 Feb 19;36(4):449-59.

PMID:
8474101
34.

Effects of high doses of A-74273, a novel nonpeptidic and orally bioavailable renin inhibitor.

Verburg KM, Polakowski JS, Kovar PJ, Klinghofer V, Barlow JL, Stein HH, Mantei RA, Fung AK, Boyd SA, Baker WR, et al.

J Cardiovasc Pharmacol. 1993 Jan;21(1):149-55.

PMID:
7678671
35.

C-terminal modifications of nonpeptide renin inhibitors: improved oral bioavailability via modification of physicochemical properties.

Boyd SA, Fung AK, Baker WR, Mantei RA, Armiger YL, Stein HH, Cohen J, Egan DA, Barlow JL, Klinghofer V, et al.

J Med Chem. 1992 May 15;35(10):1735-46.

PMID:
1588555
36.

Nonpeptide renin inhibitors employing a novel 3-aza(or oxa)-2,4-dialkyl glutaric acid moiety as a P2/P3 amide bond replacement.

Baker WR, Fung AK, Kleinert HD, Stein HH, Plattner JJ, Armiger YL, Condon SL, Cohen J, Egan DA, Barlow JL, et al.

J Med Chem. 1992 May 15;35(10):1722-34.

PMID:
1588554
37.

A phase I study of hepatic arterial infusion using difluoromethylornithine.

Lipton A, Harvey HA, Glenn J, Weidner WA, Strauss M, Miller SE, Taylor JB, White-Hershey D, Barlow JL.

Cancer. 1989 Feb 1;63(3):433-7.

PMID:
2492203
38.

Inhibition of polyamine biosynthesis by alpha-difluoromethylornithine in African trypanosomes and Pneumocystis carinii as a basis of chemotherapy: biochemical and clinical aspects.

McCann PP, Bacchi CJ, Clarkson AB Jr, Bey P, Sjoerdsma A, Schecter PJ, Walzer PD, Barlow JL.

Am J Trop Med Hyg. 1986 Nov;35(6):1153-6.

PMID:
3098121
39.

Successful treatment of lethal protozoal infections with the ornithine decarboxylase inhibitor, alpha-difluoromethylornithine.

Sjoerdsma A, Golden JA, Schechter PJ, Barlow JL, Santi DV.

Trans Assoc Am Physicians. 1984;97:70-9. No abstract available.

PMID:
6442954
40.

Terfenadine, safety and tolerance in controlled clinical trials.

Barlow JL, Beitman RE, Tsai TH.

Arzneimittelforschung. 1982;32(9a):1215-7.

PMID:
6129874
41.

Immunofluorescent detection of antibody to lymphocytic choriomeningitis virus in man.

Cohen SM, Triandaphilli IA, Barlow JL, Hotchin J.

J Immunol. 1966 May;96(5):777-84. No abstract available.

PMID:
4958095
42.

INCREASED SUSCEPTIBILITY OF MICE TO LYMPHOCYTIC CHORIOMENINGITIS VIRUS AFTER PERIPHERAL INOCULATION.

SEAMER J, BARLOW JL, GLEDHILL AW, HOTCHIN J.

Virology. 1963 Nov;21:309-16. No abstract available.

PMID:
14081355
43.

Effect of Eperythrozoon coccoides upon lymphocytic choriomeningitis in mice.

SEAMER J, GLEDHILL AW, BARLOW JL, HOTCHIN J.

J Immunol. 1961 May;86:512-5. No abstract available.

PMID:
13749489
44.

Effects of hemorrhagic shock upon the properdin system of the dog.

LEVY MN, BLATTBERG B, BARLOW JL.

J Lab Clin Med. 1960 Jul;56:105-9. No abstract available.

PMID:
14416430
45.

An internal protein in T2 and T4 bacteriophages.

LEVINE L, BARLOW JL, VAN VUNAKIS H.

Virology. 1958 Dec;6(3):702-17. No abstract available.

PMID:
13616181
46.

Studies on the inactivation of phage by the properdin system. II. Quantitative assay of phage-neutralizing activity.

BARLOW JL, VAN VUNAKIS H, LEVINE L.

J Immunol. 1958 May;80(5):349-55. No abstract available.

PMID:
13539379
47.

Studies of the inactivation of phage by the properdin system. I. Evidence for complement, properdin and magnesium requirements.

BARLOW JL, VAN VUNAKIS H, LEVINE L.

J Immunol. 1958 May;80(5):339-48. No abstract available.

PMID:
13539378
48.

The protein coats or ghosts of coli phage T2. II. The biological functions.

HERRIOTT RM, BARLOW JL.

J Gen Physiol. 1957 Nov 20;41(2):307-31.

49.
50.

NEUTRALIZATION OF BACTERIOPHAGE BY THE PROPERDIN SYSTEM.

Van Vunakis H, Barlow JL, Levine L.

Proc Natl Acad Sci U S A. 1956 Jul;42(7):391-4. No abstract available.

Supplemental Content

Loading ...
Support Center